

# Benign Prostatic Hyperplasia (BPH) Drugs-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/BCF72293BAEMEN.html>

Date: May 2018

Pages: 130

Price: US\$ 3,480.00 (Single User License)

ID: BCF72293BAEMEN

## Abstracts

### Report Summary

Benign Prostatic Hyperplasia (BPH) Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Benign Prostatic Hyperplasia (BPH) Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Benign Prostatic Hyperplasia (BPH) Drugs 2013-2017, and development forecast 2018-2023

Main market players of Benign Prostatic Hyperplasia (BPH) Drugs in United States, with company and product introduction, position in the Benign Prostatic Hyperplasia (BPH) Drugs market

Market status and development trend of Benign Prostatic Hyperplasia (BPH) Drugs by types and applications

Cost and profit status of Benign Prostatic Hyperplasia (BPH) Drugs, and marketing status

Market growth drivers and challenges

The report segments the United States Benign Prostatic Hyperplasia (BPH) Drugs market as:

United States Benign Prostatic Hyperplasia (BPH) Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England  
The Middle Atlantic  
The Midwest  
The West  
The South  
Southwest

United States Benign Prostatic Hyperplasia (BPH) Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Alpha-blocker  
Phosphodiesterase Type-5 Inhibitors  
5-alpha-Reductase Inhibitors

United States Benign Prostatic Hyperplasia (BPH) Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals  
Clinics  
Others

United States Benign Prostatic Hyperplasia (BPH) Drugs Market: Players Segment Analysis (Company and Product introduction, Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price and Gross Margin):

Astellas Pharma  
Eli Lilly  
GlaxoSmithKline  
Sanofi  
ADC Therapeutics  
Bayer HealthCare  
Bristol-Myers Squibb  
Valeant Pharmaceuticals  
Endo Pharmaceuticals  
Foresee Pharmaceuticals  
Madrigal Pharmaceuticals

Merck  
Novartis  
Spectrum Pharmaceuticals  
Takeda Pharmaceuticals  
Teva  
Advaxis  
ANI Pharmaceuticals  
BHR Pharma

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF INTRAVENOUS IRON DRUGS**

- 1.1 Definition of Intravenous Iron Drugs in This Report
- 1.2 Commercial Types of Intravenous Iron Drugs
  - 1.2.1 Ferric Carboxy Maltose
  - 1.2.2 Sucrose
  - 1.2.3 Dextran
- 1.3 Downstream Application of Intravenous Iron Drugs
  - 1.3.1 Hospital
  - 1.3.2 Drugstore
  - 1.3.3 Others
- 1.4 Development History of Intravenous Iron Drugs
- 1.5 Market Status and Trend of Intravenous Iron Drugs 2013-2023
  - 1.5.1 Global Intravenous Iron Drugs Market Status and Trend 2013-2023
  - 1.5.2 Regional Intravenous Iron Drugs Market Status and Trend 2013-2023

### **CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Development of Intravenous Iron Drugs 2013-2017
- 2.2 Production Market of Intravenous Iron Drugs by Regions
  - 2.2.1 Production Volume of Intravenous Iron Drugs by Regions
  - 2.2.2 Production Value of Intravenous Iron Drugs by Regions
- 2.3 Demand Market of Intravenous Iron Drugs by Regions
- 2.4 Production and Demand Status of Intravenous Iron Drugs by Regions
  - 2.4.1 Production and Demand Status of Intravenous Iron Drugs by Regions 2013-2017
  - 2.4.2 Import and Export Status of Intravenous Iron Drugs by Regions 2013-2017

### **CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES**

- 3.1 Production Volume of Intravenous Iron Drugs by Types
- 3.2 Production Value of Intravenous Iron Drugs by Types
- 3.3 Market Forecast of Intravenous Iron Drugs by Types

### **CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

- 4.1 Demand Volume of Intravenous Iron Drugs by Downstream Industry

## 4.2 Market Forecast of Intravenous Iron Drugs by Downstream Industry

# **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF INTRAVENOUS IRON DRUGS**

## 5.1 Global Economy Situation and Trend Overview

## 5.2 Intravenous Iron Drugs Downstream Industry Situation and Trend Overview

# **CHAPTER 6 INTRAVENOUS IRON DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS**

## 6.1 Production Volume of Intravenous Iron Drugs by Major Manufacturers

## 6.2 Production Value of Intravenous Iron Drugs by Major Manufacturers

## 6.3 Basic Information of Intravenous Iron Drugs by Major Manufacturers

### 6.3.1 Headquarters Location and Established Time of Intravenous Iron Drugs Major Manufacturer

### 6.3.2 Employees and Revenue Level of Intravenous Iron Drugs Major Manufacturer

## 6.4 Market Competition News and Trend

### 6.4.1 Merger, Consolidation or Acquisition News

### 6.4.2 Investment or Disinvestment News

### 6.4.3 New Product Development and Launch

# **CHAPTER 7 INTRAVENOUS IRON DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

## 7.1 Allergan

### 7.1.1 Company profile

### 7.1.2 Representative Intravenous Iron Drugs Product

### 7.1.3 Intravenous Iron Drugs Sales, Revenue, Price and Gross Margin of Allergan

## 7.2 AMAG Pharmaceuticals

### 7.2.1 Company profile

### 7.2.2 Representative Intravenous Iron Drugs Product

### 7.2.3 Intravenous Iron Drugs Sales, Revenue, Price and Gross Margin of AMAG Pharmaceuticals

## 7.3 Daiichi Sankyo

### 7.3.1 Company profile

### 7.3.2 Representative Intravenous Iron Drugs Product

### 7.3.3 Intravenous Iron Drugs Sales, Revenue, Price and Gross Margin of Daiichi Sankyo

## 7.4 Galenica

### 7.4.1 Company profile

### 7.4.2 Representative Intravenous Iron Drugs Product

### 7.4.3 Intravenous Iron Drugs Sales, Revenue, Price and Gross Margin of Galenica

## 7.5 Pharmacosmos

### 7.5.1 Company profile

### 7.5.2 Representative Intravenous Iron Drugs Product

### 7.5.3 Intravenous Iron Drugs Sales, Revenue, Price and Gross Margin of

## Pharmacosmos

## 7.6 Nippon Shinyaku

### 7.6.1 Company profile

### 7.6.2 Representative Intravenous Iron Drugs Product

### 7.6.3 Intravenous Iron Drugs Sales, Revenue, Price and Gross Margin of Nippon

## Shinyaku

## 7.7 NOXXON Pharma

### 7.7.1 Company profile

### 7.7.2 Representative Intravenous Iron Drugs Product

### 7.7.3 Intravenous Iron Drugs Sales, Revenue, Price and Gross Margin of NOXXON

## Pharma

## 7.8 Rockwell Medical

### 7.8.1 Company profile

### 7.8.2 Representative Intravenous Iron Drugs Product

### 7.8.3 Intravenous Iron Drugs Sales, Revenue, Price and Gross Margin of Rockwell

## Medical

## 7.9 Sanofi

### 7.9.1 Company profile

### 7.9.2 Representative Intravenous Iron Drugs Product

### 7.9.3 Intravenous Iron Drugs Sales, Revenue, Price and Gross Margin of Sanofi

## 7.10 Wanbang Biopharmaceutical

### 7.10.1 Company profile

### 7.10.2 Representative Intravenous Iron Drugs Product

### 7.10.3 Intravenous Iron Drugs Sales, Revenue, Price and Gross Margin of Wanbang

## Biopharmaceutical

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF INTRAVENOUS IRON DRUGS**

### 8.1 Industry Chain of Intravenous Iron Drugs

### 8.2 Upstream Market and Representative Companies Analysis

### 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF INTRAVENOUS IRON DRUGS**

- 9.1 Cost Structure Analysis of Intravenous Iron Drugs
- 9.2 Raw Materials Cost Analysis of Intravenous Iron Drugs
- 9.3 Labor Cost Analysis of Intravenous Iron Drugs
- 9.4 Manufacturing Expenses Analysis of Intravenous Iron Drugs

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF INTRAVENOUS IRON DRUGS**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Benign Prostatic Hyperplasia (BPH) Drugs-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/BCF72293BAEMEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BCF72293BAEMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



